Publications by authors named "Ruth N Moro"

Claim this Profile
D
Differences in Neutrophil Counts Between African and Non-African Countries in 2 International Clinical Trials.
Ruth N Moro, John L Johnson, Neil Martinson, Grace Muzanyi, Chi-Chiu Leung

J Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection.
Ruth N Moro, Carolina Mehaffy, Prithwiraj De, Elizabeth Phillips, Andrey S Borisov

J Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
Claire Sadowski, Robert Belknap, David P Holland, Ruth N Moro, Michael P Chen

Clin Infect Dis· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine.
Nigel A Scott, Claire Sadowski, Andrew Vernon, Bert Arevalo, Karlyn Beer, Ruth N Moro

Contemp Clin Trials· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US emergency department visits for acute harms from over-the-counter cough and cold medications, 2017-2019.
Rohan Mital, Maribeth C Lovegrove, Ruth N Moro, Andrew I Geller, Nina J Weidle

Pharmacoepidemiol Drug Saf· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergency Department Visits Attributed to Adverse Events Involving Benzodiazepines, 2016-2017.
Ruth N Moro, Andrew I Geller, Nina J Weidle, Jennifer N Lind, Maribeth C Lovegrove

Am J Prev Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries.
Nadine Shehab, Robert Ziemba, Kyle N Campbell, Andrew I Geller, Ruth N Moro

Pharmacoepidemiol Drug Saf· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.
Gibril J Njie, Sapna Bamrah Morris, Rachel Yelk Woodruff, Ruth N Moro, Andrew A Vernon

Am J Prev Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
Ruth N Moro, Nigel A Scott, Andrew Vernon, Naomi K Tepper, Stefan V Goldberg

Ann Am Thorac Soc· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Robert Belknap, David Holland, Pei-Jean Feng, Joan-Pau Millet, Joan A Caylà, Ruth N Moro

Ann Intern Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Amy L Sandul, Nwabunie Nwana, J Mike Holcombe, Mark N Lobato, Suzanne Marks, Ruth N Moro

Clin Infect Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada.
Ruth N Moro, Andrey S Borisov, Jussi Saukkonen, Awal Khan, Timothy R Sterling

Clin Infect Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Timothy R Sterling, Ruth N Moro, Andrey S Borisov, Elizabeth Phillips, Gillian Shepherd

Clin Infect Dis· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
M Elsa Villarino, Nigel A Scott, Stephen E Weis, Marc Weiner, Marcus B Conde, Ruth N Moro

JAMA Pediatr· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Susan E Dorman, Radojka M Savic, Stefan Goldberg, Jason E Stout, Neil Schluger, Ruth N Moro

Am J Respir Crit Care Med· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence of persistent parasitic infections in foreign-born, HIV-infected persons in the United States.
Natasha S Hochberg, Ruth N Moro, Anandi N Sheth, Susan P Montgomery, Frank Steurer

PLoS Negl Trop Dis· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis